Command: /cs:fda-qsr-audit-prep <scope>
The FDA QSR auditor pressure-tests any US medical-device QSR work. Six questions before any internal audit, FDA inspection, Form 483 response, or recall decision.
21 CFR 820.198 + 21 CFR 803 โ most-cited FDA inspection area.
Cross-walks ISO 13485 Clause 7.5.6 (substantially harmonized post-Feb 2026).
21 CFR 820.180 โ 2-year retention from commercial distribution; check sampling for completeness.
21 CFR 820.100 = ISO 13485 8.5.2 substantially harmonized.
FDA-specific overlay not in ISO 13485.
Form 483 = FDA observation; not equivalent to ISO nonconformity.
# 1. QSR compliance posture
python ra-qm-team/skills/fda-consultant-specialist/scripts/qsr_compliance_checker.py compliance_state.json
# 2. FDA submission tracking (510(k) / PMA / IDE)
python ra-qm-team/skills/fda-consultant-specialist/scripts/fda_submission_tracker.py submissions.json
# 3. HIPAA overlap (if connected device handles PHI)
python ra-qm-team/skills/fda-consultant-specialist/scripts/hipaa_risk_assessment.py phi_inventory.json
# 4. Mock FDA inspection
python ../../skills/compliance-os/scripts/audit_simulator.py fda_qsr_scope.json
# FDA QSR Audit Prep: <scope>
**Date:** YYYY-MM-DD
## The Decision Being Made
[programme-plan | inspection-readiness | 483-response | MDR-decision | recall]
## Complaint + MDR Posture
- Complaints last quarter: N
- MDR-reportable events: M
- MDR reports filed within timeline: % (target 100%)
- Complaint trending review at management level: yes/no
## Process Validation Status (21 CFR 820.75)
- Validations on schedule: %
- Stale validations: <list>
- Statistical techniques applied: yes/no per process
## DHR Completeness (21 CFR 820.180)
- DHRs sampled: N
- Completeness rate: %
- 2-year retention compliant: yes/no
- Stratified by product class: yes/no
## CAPA Health (21 CFR 820.100)
- CAPAs sampled: N
- Root cause analysis depth: adequate/inadequate
- Effectiveness verification: complete/incomplete
- Aging CAPAs > 90 days: N
## Labeling (21 CFR 801)
- Recent products reviewed: <list>
- Labeling accurate + non-misleading: yes/no
- UDI compliance per 21 CFR 830: yes/no
## Form 483 / Warning Letter History
- Form 483s last 3 years: N (each: closed/in-progress)
- Warning Letters last 5 years: N (each: closed/in-progress)
- Pattern across observations: <thematic>
## ISO 13485 Cross-Walk (post-Feb 2026 harmonization)
- ISO 13485 audit findings: <link to cs-cqm-iso13485 output>
- FDA-specific overlays remaining: labeling + complaint handling + MDR reporting + recall procedures
- Cross-framework reuse: % of evidence shared
## Verdict
๐ข INSPECTION-READY | ๐ก GAPS-IDENTIFIED | ๐ด NOT-READY
## Top 3 Actions
[3 concrete next steps with owner + FDA-cited timeline (15 days / 30 days / etc.)]
## Outside Counsel Required
[For Warning Letter response, recall decisions, or 510(k) / PMA strategy disputes]
/cs:compliance-readiness โ for multi-framework view/cs:iso13485-audit-prep โ for ISO 13485 cross-walk pair (substantially harmonized)/cs:gdpr-audit-prep โ if connected device handles personal data/cs:gc-review โ for Warning Letter response coordinationcs-fda-qsr-auditor
fda-consultant-specialist
../iso13485-audit-prep/, ../compliance-readiness/
Version: 1.0.0